Tiragolumab plus atezolizumab and chemotherapy led to significant survival improvements vs chemotherapy in patients with esophageal squamous cell carcinoma.
/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with.